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Assessing noninferiority in a three-arm trial
using the Bayesian Approach
Pulak Ghosh, Farouk S. Nathoo, Mithat Gonen, and Ram C. Tiwari

Abstract

Non-inferiority trials, which aim to demonstrate that a test product is not worse
than a competitor by more than a pre-specified small amount, are of great importance to the pharmaceutical community. As a result, methodology for designing
and analyzing such trials is required, and developing new methods for such analysis is an important area of statistical research. The three-arm clinical trial is usually recommended for non-inferiority trials by the Food and Drug Administration
(FDA). The three-arm trial consists of a placebo, a reference, and an experimental treatment, and simultaneously tests the superiority of the reference over the
placebo along with comparing this reference to an experimental treatment. In this
paper, we consider the analysis of noninferiority trials using Bayesian methods
which incorporate both parametric as well as semi-parametric models. The resulting testing approach is both flexible and robust. The benefit of the proposed
Bayesian methods is assessed via simulation, based on a study examining Home
Based Blood Pressure Interventions.
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1

Introduction

Recently, there has been a growing interest in drug development to demonstrate whether a new
treatment is not worse than that of an active control by more than a speciﬁed margin (Snapinn,
2000). This helps in assessing whether a less toxic, easier to administer, or less expensive treatment
is clinically non-inferior to a standard treatment. This kind of clinical trial, where the intention is
to investigate whether a new treatment is not inferior to the standard treatment by more than a
small predeﬁned margin, is usually known as non-inferiority trial (EMEA, 2005). There have been
a series of articles on this topic; see for example, special issues of Statistics in Medicine (Volume 47,
Issue 1, 2005) and Journal of Biopharmaceutical Statistics (Volume 14, Number 2, 2004). It is clear
that a new treatment might be preferred to a standard therapy despite it not being better than a
standard treatment. For example, the new treatment may be less invasive and less debilitating, or
it may be less expensive, and hence preferable. For these reasons, once noninferiority with respect
to the primary end point has been demonstrated, the new treatment would be an attractive option
for patients, and this is of beneﬁt to the health care system in general.
The statistical literature dealing with inference for noninferiority for two treatments has grown
substantially in the last two decades (D’Agostino et al., 2003; Munk et al., 2005; Koti, 2007).
Two-arm noninferiority trials of a test treatment and a well established reference treatment are
an attractive option in that, in certain settings, there is no need to expose patients to a placebo.
Nevertheless, two-arm noninferiority trials exhibit some major challenges in terms of design, analysis
and interpretation (Jones et al., 1996; Rohmel, 1998; Temple et al., 2000; D’Agostino et al., 2003;
Koch and Rohmel, 2004). Most two-arm trials lack the support of the assay sensitivity resulting
in an inability of the trial to distinguish between test and active control treatments. As a result,
the inclusion of a placebo group into trials comparing active treatments is useful, whenever this is
ethical (Kieser and Friede, 2007; Koti 2007).
Recently, Pigeot et al. (2003) and Koch and Rohmel (2004) considered three-arm trials with both
a known eﬀective active standard treatment/drug and placebo as control groups. These three-arm
noninferiority trials are useful as they avoid the diﬃculties described above. In this case, eﬃcacy
of the test treatment can be demonstrated by direct comparison to the placebo; however, a major
limitation of these methods is the assumption of a homogenous variance in the response variables
collected across the treatment arms. Along these lines, while noninferiority trials have generated
considerable research in last few decades, there have been few attempts to address noninferioity
2
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under a heteroscedastic variance assumption. Recently, Hasler et al. (2007) and Koti (2007)
have considered the analysis of noninferiority trials in three treatment arms in the presence of
heteroscadesticity. Hasler et al. (2007) used a t-distribution to test the noninferiority hypothesis;
whereas, Koti (2007) has developed a new test procedure based on the Fieller-Hinkley distribution.
In this paper, we put forth a novel Bayesian approach for the analysis of noninferiority trials
under three treatments in the presence of heteroscadesticity. A fully Bayesian approach can have
important advantages in accounting fully for various sources of uncertainty, and incorporating prior
information (Gill, 2002; Gelman et al. , 2004). Posterior distributions can be computed eﬃciently
and accurately using simulation based methods, and inference relating to non-inferiority testing can
proceed without resorting to asymptotics, which is useful with small sample studies. In addition,
as a non-inferiority trial involves treatments that have been well-studied in the past, it is plausible
that prior information is available, and the ability to incorporate such information is an advantage.
Finally, the Bayesian approach circumvents the diﬃculties encountered with traditional methods
for hypothesis testing (Ghosh and Gönen, 2008), as the hypotheses of interest are assessed based
on the posterior probability distribution, and not on p-values which are often misinterpreted.
Another potential drawback associated with existing methodology for non-inferiority testing is the
assumption of normally distributed response variables. In general, inferences based on the normality
assumption can be misleading when this assumption is not adequate (Ghosh and Gönen, 2008), and
more ﬂexible methods would be useful in many settings. More speciﬁcally, methods based on scale
mixtures of the normal distribution are useful to consider, allowing for heavier-tailed distributions
and leading to robust procedures. Thus, it is of practical interest to develop statistical models for
noninferiority trials that move beyond the traditional parametric normal model. We develop here
robust parametric and semiparametric Bayesian modeling approaches to assess noninferiority. To
develop this approach we use mixtures of Dirichlet processes (MDP) (MacEachern, 1994; Escober
and West, 1995; MacEachern and Muller, 1998; Ghosh, Basu and Tiwari, 2009) which lead to
ﬂexible models for data exhibiting non-normal behavior. Aside from gaining ﬂexibility, our use of
the MDP also facilitates an implementation in standard software for Bayesian computing, and this
is a practical advantage.
In Section 2 we review the three arm noninferiority trial, and in Section 3 we describe parametric
methods for analysis under heteroscedasticity. These methods are then extended in Section 4, we
present our semi-parametric Bayes approach, which allows for ﬂexibility under a wide range of

3

Hosted by The Berkeley Electronic Press

distributions. In Section 5 we describe the Home-Based Blood Pressure Intervention trial, which
forms the basis of a simulation study conducted in Section 6. Finally, Section 7 draws conclusions
and provides an outlook on future research.

2

Hypothesis testing in a three-arm noninferiority trial

There have been two main approaches adopted for testing in noninferiority trials. The traditional
approach ﬁrst deﬁnes a noninferiority margin δ, and then demonstrates that the eﬀect of the
experimental treatment is not worse than the eﬀect of the control by more than this amount. This
is referred to as the ﬁxed-margin approach (Koch and Rohmel, 2004). The second approach involves
directly combining the point estimate and variance from the noninferiority trial with those from
historical trials, and is referred to as the synthesis approach (Koch and Rohmel, 2004). In this
work we shall follow the traditional ﬁxed-margin approach as described below.
Let XE,i , XR,j , XP,k , (i = 1, 2, · · · , nE ; j = 1, 2, · · · , nR ; k = 1, 2, · · · , nP ) denote the random
variables corresponding to observations taken from the experimental, reference, and placebo groups
respectively. We assume that these random variables are mutually independent and that
i.i.d.
i.i.d.
i.i.d.
2
2
XE,i ∼ N (µE , σE
), XR,j ∼ N (µR , σR
), XP,k ∼ N (µP , σP2 )

(1)

so that we allow for heteroscedasticity across treatment arms, but assume normally distributed
response variables, an assumption that will be relaxed in Section 4. Commonly, for a two-arm trial,
the noninferiority hypothesis is formulated as
H0 : µE − µR ≤ δ

vs Ha : µE − µR > δ

(2)

where δ < 0 denotes the pre-speciﬁed maximal clinically irrelevant amount, and is called the
amount of noninferiority margin. The choice of δ in a clinical trial depends on a combination
of statistical reasoning and clinical judgement. See the Concept Paper on the development of a
Committee for Proprietary Medicinal Products (CPMP, 2005) guidelines for more on the choice of
the noninferiority margin δ. Essentially, a rejection of the null hypothesis is required to demonstrate
noninferiority support of the experimental treatment to the reference treatment.
When a placebo group is included in the trial, one can formulate δ as a negative fraction f of the
unknown diﬀerence in mean response between the reference and placebo (Pigeot et al., 2003), that
is δ = f (µR − µP ), where f is a fraction ranging between 0 < f < 1. Assuming, µR − µP > 0 and
4
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employing this expression for δ in the hypothesis (2) we obtain
H0 : µE − µR ≤ f (µR − µP ) vs

Ha : µE − µR > f (µR − µP ).

(3)

Next we let θ = (1 + f ) so that (3) can be written as
H0 :

µE − µP
≤θ
µR − µP

vs

Ha :

µE − µP
> θ,
µR − µP

(4)

where θ is the prespeciﬁed fraction of the eﬀect of the reference drug (relative to placebo) that
we require for the eﬀect of the test drug (relative to placebo), in order to declare noninferiority.
According to CPMP (1999), reasonable choices of f include − 12 , − 31 , − 15 ; however, it should also
be mentioned that while making this choice, a clinical consideration should be applied in practice.
The alternative hypothesis in (4) implies that the test treatment achieves more than θ × 100% of
the eﬃcacy of the reference treatment, each compared to placebo. Pigeot et al. (2003) have shown
that diﬀerent choices of θ are chosen for diﬀerent purposes. In particular, noninferiority of test
treatment to the reference treatment is evaluated through a test of H0 in (4) with 1 + f < θ < 1;
and 0.5 ≤ θ < 1 (Koch and Tangen, 1999).
For the derivation of the statistical test procedures for the test problem (4), it is helpful to express
(4) as:

H0 : µE − θµR − (1 − θ)µP ≤ 0

vs Ha : µE − θµR − (1 − θ)µP > 0

(5)

Pigeot et al. (2003) derived a Student-t statistic based on Fieler’s conﬁdence interval. They
also considered a bootstrap percentile interval as an alternative to Fieler’s method in case the
assumption of normality does not hold. More recently, Hasler et al. (2007) extended the results to
the situation where the group variances are heterogenous.

3
3.1

Bayesian Analysis
Prior distribution

Our ﬁrst approach is based on a fully parametric model, where we specify a prior distribution for
location and scale parameters (µl , σl2 ), l ∈ {E, P, R} using a normal-inverse-gamma distribution
µl |σl2 ∼ N (µ0l , σl2 |κ0l ), and
2
σl2 ∼ Inv-gamma(ν0l /2, σ0l
ν0l /2), l ∈ {E, R, P }

5
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2 are ﬁxed hyperparameters. The appearance of σ 2 in the conditional distriwhere µ0l , κ0l , ν0l , σ0l
l

bution of µl |σl2 calibrates the prior information on µl to the scale of measurement in the observed
data, with κ0l ≥ 0 representing the number of prior observations on this scale. The prior sample
size κ0l can be adjusted with reference to the observed sample size nl , and is an intuitive measure
2 are chosen
characterizing the degree of prior information on µl . The hyperparameters ν0l and σ0l

to reﬂect prior information on the scale parameters σl2 . These variance components are typically
nuisance parameters and a noninformative prior can be obtained by letting ν0l → 0, resulting in
p(σl2 ) ∝ σl−2 . Next we condition on µR − µP > 0, leading to a truncated prior having density of the
form

p(µ, σ) ∝ I{µR > µP }

∏

2
p(µl , σl2 |µ0l , κ0l , ν0l , σ0l
)

(6)

l∈{E,P,R}
2 ) = p(µ |µ , κ , σ 2 )p(σ 2 |ν , σ 2 )
where I{·} denotes the indicator function and p(µl , σl2 |µ0l , κ0l , ν0l , σ0l
l 0l 0l l
l 0l 0l
2 ) the density
, with p(µl |µ0l , κ0l , σl2 ) the density of the N (µ0l , σl2 /κ0l ) distribution and p(σl2 |ν0l , σ0l

of the Inv-gamma( ν20l ,

2 ν
σ0l
0l
2 )

distribution.

In practice, analysis can be performed under several choices of prior parameters. Two such
extreme choices are often called skeptical and enthusiastic priors. In a clinical trial of superiority,
for example, one might center the prior for treatment diﬀerence in favor of the experimental arm
to represent an enthusiastic prior (and vice versa for the skeptical prior). In the case of a noninferiority trial with three arms such choices are not immediate. Here we have some suggestions
for the practicing Bayesian statistician.

3.2

Posterior Distribution

The non-inferiority hypothesis (??) is evaluated under the marginal posterior distribution [µ|X],
where X = {XE,i , XR,j , XP,k , i = 1, 2, · · · , nE ; j = 1, 2, · · · , nR ; k = 1, 2, · · · , nP } denotes the
observed data. Under the Gaussian assumption for the response variables, and under the prior
(??), the density of this posterior arises through the product of three student-t densities, where
again, the distribution is truncated so that µR > µP
p(µE , µP , µR |X) ∝ I{µR > µP }

∏

tνnl (µl |µnl , σnl )

(7)

l∈{E,P,R}
2 −(ν+1)/2 denotes the density function of the student-t distribution
where tν (x|µ, σ) ∝ (1 + ν1 ( x−µ
σ ) )

on ν degrees of freedom, with location µ and scale σ. For each l ∈ {E, P, R}, the parameters of the
6
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posterior distribution are obtained in closed form as νnl = ν0l + nl ; µnl =
2
σnl
=

κ0l
κ0l +nl µ0l

l
+ κ0ln+n
X̄l , and
l

2
ν0l σ0l
(nl − 1)Sl2
κ0l nl (µ0l − X̄l )2
+
+
(ν0l + nl )(κ0l + nl ) (ν0l + nl )(κ0l + nl ) (ν0l + nl )(κ0l + nl )2

where X̄l and Sl2 , l ∈ {E, P, E} are the corresponding sample mean and variance from group
l. Inference and, in particular, calculation of the posterior probability of H1 in (??) is based on
drawing samples from the posterior distribution (??), which is easily accomplished by drawing
independent student-t random variables tνnl (µl |µnl , σnl ), in conjunction with rejection sampling to
ensure that µR > µP .

3.3

Test Procedure

In determining whether the experimental drug is non-inferior or not, it is necessary for an investigator to pick a value for θ which is the required cut-oﬀ point in order for the experimental drug
to be non-inferior than the active control. Then the clinician ﬁnds the posterior probability of
the hypothesis (??). The experimental drug is said to be non-inferior to the active control if this
posterior probability is greater than the some pre-speciﬁed cut-oﬀ point, say, RNI . Thus, one will
declare the experimental drug to be non-inferior if
P (H1 :

µE − µP
> θ|Data) > RNI
µR − µP

Calculation of the above posterior probability in our case is straightforward. If we can draw T
values from the posterior distribution of

µE −µP
µR −µP

we can estimate this probability by

T
µE − µP
1 ∑ µlE − µlP
I( l
Pb(H1 :
> θ|Data) =
> θ)
l
µR − µP
T
µ
−
µ
R
P
l=1

where, µlE , µlP , µlR are respectively the values of µE , µP , µR in the lth iteration of the algorithm.
The choice of RNI is highly consequential. A reasonable default value might be 0.5, which
essentially means that, between the null and alternative, the hypothesis with the higher posterior
probability is retained. However, in some contexts it may be useful to consider higher values of
RNI , depending on the operating characteristics needed.

4

Semiparametric Extensions

There could be instances where XE , XR , XP are skewed or multimodal and thus far from normal.
While a natural procedure is to use some ad-hoc transformation to achieve normality, a normalizing
7
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transformation on the original data should be avoided if a more suitable parametric model can
be found. This is mainly because transformations sometimes may not be useful as it changes the
original unit of the data, which, in turn, makes it diﬃcult to interpret and communicate the ﬁndings.
In addition, it is often not straightforward, or impossible, to discover the right transformations. To
address this need we also consider modeling these responses by a Dirichlet process mixture (DPM)
model. This new approach creates a model and inference procedure that is robust to departures
from the assumption of normality.
The DPM models have recently become computationally feasible with development of MCMC
methods for sampling from the posterior distribution of the Dirichlet process (Escobar, 1994; Escobar and West, 1998; MacEachern, 1994; Ishwaran and James, 2001). The DPM models are by far
the most widely used semiparametric Bayesian models, mainly because of the ease of computation,
and ability to characterize diﬀerent shapes.
Suppose, as before, the observed response is {Xi }. We drop the treatment subscript l ∈ {E, P, R}
for the diﬀerent treatment for the time being. Under the error-DPM model we assume that Xi
follows a scale mixture of normal DPM whose density (with respect to Lebesgue measure) is given
by

∫
f (Xi |µi , G) =

ϕ(Xi |µi , ξi ζ) dG(ξi ).

(8)

Here ϕ(X|µ, τ ) denotes the density of the N (µ, ζ −1 ) distribution. The key feature of the model
is the assumption that the scale mixing distribution G is unknown, and is modeled by a Dirichlet
process (DP) prior with concentration parameter ν and speciﬁed base probability measure G0 (·|κ)
that depends on an unknown parameter vector κ (G and G0 here denote probability measures
although we often refer to them as distributions). This model can be expressed hierarchically as
Xi | µi , ξi , ζ

(
)
indep
∼
N µi , variance=ξi−1 ζ −1 , i = 1, . . . , n

ξ1 , . . . , ξn | G

iid
∼

G

G | ν, κ, G0

∼

DP(ν, G0 (·|κ))

(ζ, κ, ν)

∼

π(ζ) π(κ) π(ν) ,

(9)

with the mean µ. The Bayesian model speciﬁcation for the error-DPM model is completed by
assigning prior probability models for the hyperparameter vector κ of G0 and the concentration
parameter ν. We will use a Gamma(s/2, s/2) distribution for the base measure, G0 (.) We note here
that the class of normal- scale mixtures is quite broad and includes many popular heavier tailed
8
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distributions such as the Logistic family and the t-family of distributions; distributions which are
often used in robust statistical procedures.
There are several ways to implement a DPM prior. Recent research has focused on using the
following constructive deﬁnition of the DP (Sethuraman and Tiwari, 1982; Sethuraman, 1994) to
produce MCMC algorithms
G(·) =

∞
∑

iid

pr δZr (·); where Zr ∼ G0 (·|κ),

(10)

r=1

with p1 = V1 , pr = Vr

r−1
∏

iid

(1 − Vj ), and Vr ∼ Beta(1, ν), r ≥ 1

(11)

j=1

If we truncate the sum in (??) at a large integer R > 0 we obtain the models considered in Ishwaran
and Zarepour (2002), Ishwaran and James (2001, 2002). This reduces G(·) into ﬁnite dimensional
R
∑
form as G =
pr δZr (·). The model in (??) can then be expressed hierarchically as
r=1

Xi |Z = (Z1 , · · · , ZR ), s, µi

ind

∼

ϕ(Xi |µi , ζ Zsi ), i = 1, . . . , n

si |p

iid

R
∑

∼

pr δr (·),

(12)

r=1
iid

where si is the latent mixture component indicator for the ith observation, s = (s1 , . . . , sn ), Zr ∼

G0 (·|κ), and the distribution of p = (p1 , . . . , pR ) is speciﬁed by the stick-breaking construction. The
so-called blocked Gibbs sampler updates Z, s and p in multivariate blocks. Another advantage here
is that since the DPM structure is reduced to a ﬁnite mixture model by this truncation and a nonconjugate structures can be more easily handled now. The eﬀect of truncation on the distribution of
functionals of a Dirichlet process has been studied by Ohlssen, Sharples, and Spiegelhalter (2007),
√
and Ishwaran and Zarepour (2002). Ishwaran and Zarepour (2002) suggest taking R = n for large
n, and R = n for small n. We follow the suggestion of Ishwaran and Zarepour (2002) in choosing
R.
Based on the above idea, we now put a DPM prior on the distribution of the experimental drug,
active control and the placebo as follows:

9
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−1 2
−1 2
−1 2
XE,i ∼ N (µE , γ1i
σ ), XR,j ∼ N (µR , γ2j
σ ), XP,k ∼ N (µP , γ3k
σ )

γEi ∼ G1 ,

, γRj ∼ G2 ,

G1 ∼ DP (ν1 , G01 ),

5

γP k ∼ G3

G2 ∼ DP (ν2 , G02 ),

(13)
(14)

G3 ∼ DP (ν3 , G03 )

(15)

G0k ∼ Gamma(a, b),

k = 1, 2, 3

(16)

νk ∼ Gamma(c, d),

k = 1, 2, 3

(17)

Example: Home-Based Blood Pressure Interventions

The method was motivated by the design of a randomized trial to assess the eﬀectiveness of organizational interventions at improving blood pressure (BP). Home health care is a non-institutional
setting that provides services to a high-risk population characterized by multiple chronic conditions
and signiﬁcant needs for both medical and self-care management. Several patients in home health
care have essential hypertension (HTN), but for various reasons management of blood pressure for
patients with HTN has traditionally received less attention than the management of other chronic
conditions such as diabetes and chronic obstructive pulmonary disease. For this reason a randomized trial is proposed that will examine the eﬀectiveness of two organizational interventions aimed
at improving BP control among a high-risk home care population. The two interventions to be
tested include (i) a ”basic” intervention delivering key ”just-in-time” information to nurses, physicians and patients while the patient is receiving traditional post-acute home health care; and (ii)
an ”augmented” intervention transitioning patients to a Home-Based HTN Support Program that
extends the information, monitoring and feedback available to patients and primary care physicians
for an 18-month period beyond an index home care admission. Usual care is included as a third
arm. The primary goal is to see if the basic intervention is at least as good as the augmented
one, relative to the usual care. In the terminology of Section 3, usual care is the placebo group,
augmented care is the reference group and basic care is the experimental group.
As this trial has been designed but not completed the simulation studies in the next section
are motivated by this example. Note that, because of the nature of the delivery of home health
care, it was decided to randomize the caregivers (nurses) instead of patients, thus making this a
cluster-randomized study.

10
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5.1

Simulation Studies

We consider data generation under two scenarios, normally distributed values of the logarithm of
the blood pressure as well as a heavier-tailed distribution ( Laplace distribution) as the second case,
to assess the robustness of our method and its semiparametric extension. The Laplace distribution
has density f (x) =

1
2σ

exp(− 1b |x − µ|).

Since the trial is 1:1:1 randomized we are taking nE = nR = nP = 150. Using the preliminary
2 = 5, σ 2 = 3
data that was gathered to design the trial we are estimating µP = 1, µR = 4.9, σE
R

and σP2 = 1. We consider two clinically diﬀerent scenarios: a non-inferior scenario where µE = 5
and an inferior scenario on were µE = 3. Also we considered a range of values for µE as described
next.
When clustering is taken into account, the entire data generation process is replicated with 50
caregivers randomized to each arm and each caregiver is assumed to have three patients keeping
the sample size at 150 per arm. Patients within a caregiver are assumed exchangeable with a
correlation of 0.1.
The values of the hyperparameters associated with means and variances are listed in the setup
below. For the DP models, we take the base-measures, G0k to be Gamma(s/2, s/2) with s ∼
√
unif orm(1, 100) and the concentration parameter νk ∼ Gamma( n, 1) where n is the sample in
the given group.
Here we present the results of two simulation studies examining the performance of the proposed methods. In each case, for a given set of parameter values µl , σl , l ∈ {E, P, R}; sample sizes
nl , l ∈ {E, P, R}; and eﬀectiveness threshold θ; the performance is evaluated through the expected
posterior probability of non-inferiority E[P (H1 |Data)], where the expectation is taken with respect
to the sampling distribution, generating repeated realizations of the data. In the ﬁrst study, we
assume a Gaussian sampling distribution, applying the model described in Section 2, and illustrate
the impact of prior information under various sample size assumptions. In the second study, heavier tailed sampling distributions are considered, and we examine the performance of the Gaussian
model under misspeciﬁcation, and compare this performance with that of the semiparametric scale
mixture model proposed in Section 3.

Design of simulations 1:
11
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• Assume nE = nP = nR = n and θ = 0.8
2 = 5, σ 2 = 3, σ 2 = 1
• Set σE
R
P

• Set µP = 1, µR = 4.9 and let µE vary from µE = 2.95, 2.96, . . . , 6.01 so that

µE −µP
µR −µP

covers a

range of values from 0.5 to 1.2.
• For a given value of

µE −µP
µR −µP

, generate data, and compute P (H1 |Data) under the three priors

considered. Repeat nsim = 1000 times and compute the average as a Monte Carlo estimate
of E[P (H1 |Data)] for each of the three priors.
• For the three priors considered, we set ν0l = 0 so that they are all uninformative with respect
to the variance parameters. The three priors vary according to hyperparameters κ0l and µ0l ,
which represent, respectively, the prior sample size and prior mean of µl
1. noninformative prior: κ0l = 0, µ0l = 0, l ∈ {E, R, P }
2. enthusiastic prior: κ0l = 10, l ∈ {E, R, P }, µ0E = 4, µ0R = 3, µ0P = 1
3. skeptical prior: κ0l = 10, l ∈ {E, R, P }, µ0E = µ0P = 1, µ0E = 3
• Repeat over the entire range of values for

µE −µP
µR −µP

in order to generate a curve for each prior.

• Generate curves for four diﬀerent sample sizes: n = 20, 50, 100, 150
Results are depicted in Figure 1. Within each panel of Figure 1, we see that as the prior moves
from enthusiastic to skeptical, the posterior probability of H1 decreases for each value of (µE −
µP )/(µR − µP ), as expected. Moving from one panel to the other, we observe that the eﬀect
of increasing sample size is making each curve more steep (and hence more likely to reject H1 )
and also closer to one another (hence robust to prior speciﬁcation). Both of these behaviors are
intuitive and expected. Furthermore, since θ = 0.8, one would consider (µE − µP )/(µR − µP ) >
0.8 corresponding to the case where the alternative is true. The non-informative prior yields
approximately 0.5 posterior probability at that point, for all sample sizes considered, suggesting
that it is well calibrated.
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Figure 1: Study 1: Curves depicting expected posterior probability of non-inferiority
−µP
E[P (H1 |Data)] as a function of µµER −µ
for each of the three priors considered. These based on
P
2
2
2
θ = 0.8, σE = 5, σR = 3,σP = 1, µP = 1, µR = 4.9 and nE = nP = nR = n with (a) n = 20; (b)
n = 50; (c) n = 100; (d) n = 150.
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Design of simulations 2:
• Replace the Gaussian sampling distribution with data simulated from (1) a t-distribution
with DF = 2 and (2) a Laplace distribution.
2 = 5, σ 2 = 3, σ 2 = 1, µ = 1,
• Location and scale parameters are set as in study 1, with σE
P
R
P

µR = 4.9 and we let µE vary from µE = 2.95, 2.96, . . . , 6.01 so that

µE −µP
µR −µP

covers a range of

values from 0.5 to 1.2.
• Assume nE = nP = nR = 20 and θ = 0.8
• Fit the Gaussian model and generate curves depicting E[P (H1 |Data)] for each of the three
priors, based on nsim = 100 data replications.
• Fit the DP scale mixture model and generate curves depicting E[P (H1 |Data)] for each of
the three priors, based on nsim = 100 data replications. Compare to results obtained from
Gaussian model.
• The noninformative, skeptical and enthusiastic priors on location and scale parameters are
assumed to be the same as in study 1. For the DP model, winbugs does not allow improper
priors, so we approximate the prior described in Section 3.1 by taking ν0l = 0.001 (as opposed
to ν0l = 0) in the prior for variance components; and κ0l = 0.001 (as opposed to κ0l = 0) in
the noninformative prior for the location parameters.
Results are depicted in Figure 2.

The upper three panels correspond to the t2 simulation

for the three diﬀerent priors: non-informative (a), skeptical (b) and enthusiastic (c). For the
non-informative prior, we see that the posterior probabilities of DP and Gaussian cross around
(µE − µP )/(µR − µP ) = 0.8, the value of θ used in the simulations, again showing excellent prior
calibration. For values (µE −µP )/(µR −µP ) > 0.8 the DP model gives higher posterior probabilities,
and hence more power, than the Gaussian model. For values (µE − µP )/(µR − µP ) < 0.8 the DP
model gives lower posterior probabilities which implies an appropriate level of conservatism under
the null hypothesis. The results from the skeptical model are also similar, the only diﬀerence being
that posterior probabilities for both models are proprtionately smaller than those observed with
the non-informative prior. Hence the price of insisting on a parametric model when it is wrong,
results in an increase in the number of both false positive and false negative decisions. While the
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enthusiastic model shows a similar pattern, the curves cross earlier since it takes a smaller signal
to convince the enthusiast.
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Figure 2: Study 2: Curves depicting expected posterior probability of non-inferiority
−µP
E[P (H1 |Data)] as a function of µµER −µ
for the Gaussian and DP models. These based on θ = 0.8,
P
2
2
2
σE = 5, σR = 3,σP = 1, µP = 1, µR = 4.9 and nE = nP = nR = n = 20. Panels (a), (b) and
(c) correspond to data simulated from a t2 distribution and models based on the noninformative,
skeptical and enthusiastic prior respectively. Panels (d), (e) and (f) correspond to data simulated
16
from a Laplace distribution and models based on the noninformative, skeptical and enthusiastic
prior respectively.
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6

Discussion

In this paper we have developed two Bayesian approaches for hypothesis testing in non-inferiority
trials under a three-arm design. One is a parametric model, relying on normality of the data and
the other is nonparametric using a Dirichlet process prior. The latter has the advantage of accommodating data from skewed or thick-tailed distributions without requiring a transformation. Our
method has the advantage of accommodating heteroscedasticity, a common simplifying assumption in the literature, which is unlikely to hold in many cases. Finally we take full advantage of
the Bayesian framework both conceptually, by using the posterior probabilities for inference, and
computationally, by using MCMC to accommodate the Dirichlet process prior.
We applied our method to an ongoing trial investigating an intervention to blood pressure management in the home care setting. Since the data are not yet available, we simulated under the
conditions presumed in the study protocol. The results suggest that the method works well under a
variety of priors. While the parametric method is eﬃcient when correct, it may suﬀer considerably
when there are substantial deviations. We recommend routine use of the DPM unless there is
strong support for the parametric assumptions.
We are currently working on extensions to binary and censored data, where similar principles
apply, although implementations may diﬀer substantially.
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